European Production Facilities
Highest International Standard
In Europe we have two production facilities in Pfaffenhofen (Germany) and Altkirch (France), both approved by national and international authorities such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) or the German Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte or BfArM). Our manufacturing facilities comply with GMP (Good Manufacturing Practices) standards.
State-of-the-art equipment and automation using the latest technology ensure consistently high production quality. In our global pharmaceutical production operations, the role of our Pfaffenhofen production plant continues to expand.
The site makes an important contribution to global production capacity. The whole family of our olmesartan products is produced in Pfaffenhofen and shipped from this location to many countries worldwide.
Pfaffenhofen: Pharmaceutical Goods Worldwide
More than 28 million packages and approximately 2 billion tablets of our products can be produced each year at our site located in the German state of Bavaria. From here, they are shipped throughout the world. In co-operation with licensees, we distribute pharmaceutical goods to more than 50 countries worldwide, including toll manufacturing for the U.S. and Asian markets. Pfaffenhofen's activities comprise biotechnology manufacturing and the production of semisolid, liquid (ointments, gels) and solid (tablets and film-coated tablets) pharmaceutical products. In our production facility in Altkirch, France, we manufacture active pharmaceutical ingredients for our traditional Luitpold products.
Our Pfaffenhofen site plays also a key role in pharmaceutical development and assumes a leading role globally for an increasingly large number of galenic research projects. In the pharmaceutical development department in Pfaffenhofen, more than 70 employees work on development projects for Daiichi Sankyo worldwide.
The department is integrated into our global research structure and reports directly to the Group’s Global Head of Research.
Our German team investigates how active ingredients are metabolised, defines the optimal formulation for the related medicine, examines the best production methods for the drug and evaluates the stability of the new drug formulation.